Enfusion, Inc.

NYSE:ENFN Stock Report

Market Cap: US$1.3b

Enfusion Balance Sheet Health

Financial Health criteria checks 6/6

Enfusion has a total shareholder equity of $96.2M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $134.9M and $38.8M respectively. Enfusion's EBIT is $11.2M making its interest coverage ratio -7. It has cash and short-term investments of $48.3M.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ratio-7x
CashUS$48.30m
EquityUS$96.18m
Total liabilitiesUS$38.76m
Total assetsUS$134.94m

Recent financial health updates

Here's Why We're Not At All Concerned With Enfusion's (NYSE:ENFN) Cash Burn Situation

Feb 08
Here's Why We're Not At All Concerned With Enfusion's (NYSE:ENFN) Cash Burn Situation

Recent updates

Enfusion: Revenue Growth Should Start To Accelerate

Dec 24

Is There An Opportunity With Enfusion, Inc.'s (NYSE:ENFN) 32% Undervaluation?

Nov 23
Is There An Opportunity With Enfusion, Inc.'s (NYSE:ENFN) 32% Undervaluation?

Why Private Equity Will Buyout Enfusion

Oct 29

Enfusion: Growth Should Accelerate In Coming Quarters

Aug 19

Investors Can Find Comfort In Enfusion's (NYSE:ENFN) Earnings Quality

Aug 14
Investors Can Find Comfort In Enfusion's (NYSE:ENFN) Earnings Quality

Enfusion: Expectations Of Faster Growth And Higher Margins Justify A Buy Rating

Jun 16

Is Now An Opportune Moment To Examine Enfusion, Inc. (NYSE:ENFN)?

Mar 13
Is Now An Opportune Moment To Examine Enfusion, Inc. (NYSE:ENFN)?

Capital Allocation Trends At Enfusion (NYSE:ENFN) Aren't Ideal

Feb 19
Capital Allocation Trends At Enfusion (NYSE:ENFN) Aren't Ideal

Enfusion: Product Is Sticky And Industry Is Huge

Jan 18

Calculating The Fair Value Of Enfusion, Inc. (NYSE:ENFN)

Jan 04
Calculating The Fair Value Of Enfusion, Inc. (NYSE:ENFN)

Investors Appear Satisfied With Enfusion, Inc.'s (NYSE:ENFN) Prospects As Shares Rocket 28%

Dec 02
Investors Appear Satisfied With Enfusion, Inc.'s (NYSE:ENFN) Prospects As Shares Rocket 28%

Enfusion: Still Bullish Considering Q3 EBITDA Beat

Nov 08

Why Enfusion, Inc. (NYSE:ENFN) Could Be Worth Watching

Oct 31
Why Enfusion, Inc. (NYSE:ENFN) Could Be Worth Watching

Enfusion Faces Cross-Currents In Investment Management Software Market

Aug 24

Enfusion, Inc. Just Missed Earnings - But Analysts Have Updated Their Models

Aug 11
Enfusion, Inc. Just Missed Earnings - But Analysts Have Updated Their Models

Enfusion: Multiple Catalysts

Jun 20

Enfusion, Inc.'s (NYSE:ENFN) Intrinsic Value Is Potentially 32% Above Its Share Price

Mar 08
Enfusion, Inc.'s (NYSE:ENFN) Intrinsic Value Is Potentially 32% Above Its Share Price

Here's Why We're Not At All Concerned With Enfusion's (NYSE:ENFN) Cash Burn Situation

Feb 08
Here's Why We're Not At All Concerned With Enfusion's (NYSE:ENFN) Cash Burn Situation

Enfusion brings on Shift4 Payments' Brad Herring as CFO

Dec 19

Enfusion Expands Offerings As Revenue Growth Decelerates

Oct 31

Enfusion, Inc. (NYSE:ENFN) Shares Could Be 49% Below Their Intrinsic Value Estimate

Oct 18
Enfusion, Inc. (NYSE:ENFN) Shares Could Be 49% Below Their Intrinsic Value Estimate

Enfusion gains after takeover report

Aug 31

Financial Position Analysis

Short Term Liabilities: ENFN's short term assets ($85.4M) exceed its short term liabilities ($23.6M).

Long Term Liabilities: ENFN's short term assets ($85.4M) exceed its long term liabilities ($15.2M).

Debt to Equity History and Analysis

Debt Level: ENFN is debt free.

Reducing Debt: ENFN had no debt 5 years ago.

Debt Coverage: ENFN has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: ENFN has no debt, therefore coverage of interest payments is not a concern.

Balance Sheet

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 07:47
End of Day Share Price 2024/12/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Enfusion, Inc. is covered by 12 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Koji IkedaBofA Global Research
Kevin McVeighCredit Suisse
Parth TalsaniaEquisights